Morepen Laboratories Ltd vs Walpar Nutritions Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.99 as of 04 May 10:56 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Walpar Nutritions Ltd changed from 32.1 on March 2022 to 17.1 on March 2025 . This represents a CAGR of -14.57% over 4 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Walpar Nutritions Ltd changed from ₹ 12.26 crore on March 2022 to ₹ 39.72 crore on March 2025 . This represents a CAGR of 34.16% over 4 years The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The revenue of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The ebitda of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The net profit of Walpar Nutritions Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Walpar Nutritions Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Walpar Nutritions Ltd

Walpar Nutritions Limited was originally formed and registered as a Partnership Firm in the name and style of 'M/s Walpar Healthcare', pursuant to a Deed of Partnership dated November 16, 2009.
Subsequently, the Constitution of Partnership Firm were changed on March 9, 2015, August 15, 2017 and June 12, 2020 by admission and retirement of Partners. 'M/s.
Walpar Healthcare' was thereafter converted from a erstwhile Partnership Firm to a Public Limited Company as 'Walpar Nutritions Limited' and received a Certificate of Incorporation dated December 4, 2020 from the Central Registration Center, Ministry of Corporate Affairs.
The Company is primarily engaged in manufacturing, marketing and trading of Pharmaceuticals, Nutraceutical, Herbal and Ayurvedic commodities online and offline. The Company made a public issue of 12,00,000 Equity Shares of having Face Value of Rs.

FAQs for the comparison of Morepen Laboratories Ltd and Walpar Nutritions Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Walpar Nutritions Ltd?

Market cap of Morepen Laboratories Ltd is 2,269 Cr while Market cap of Walpar Nutritions Ltd is 34 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Walpar Nutritions Ltd?

The stock performance of Morepen Laboratories Ltd and Walpar Nutritions Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Walpar Nutritions Ltd?

As of May 4, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.41. On the other hand, Walpar Nutritions Ltd stock price is INR ₹37.0.

How do dividend payouts of Morepen Laboratories Ltd and Walpar Nutritions Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Walpar Nutritions Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.